FR2480123A1 - Nouveau vaccin contre la rage - Google Patents
Nouveau vaccin contre la rage Download PDFInfo
- Publication number
- FR2480123A1 FR2480123A1 FR8008414A FR8008414A FR2480123A1 FR 2480123 A1 FR2480123 A1 FR 2480123A1 FR 8008414 A FR8008414 A FR 8008414A FR 8008414 A FR8008414 A FR 8008414A FR 2480123 A1 FR2480123 A1 FR 2480123A1
- Authority
- FR
- France
- Prior art keywords
- sep
- virus
- passages
- passage
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000699670 Mus sp. Species 0.000 title claims abstract description 15
- 229960003127 rabies vaccine Drugs 0.000 title claims abstract description 5
- 210000003296 saliva Anatomy 0.000 title claims abstract description 4
- 241000700605 Viruses Species 0.000 claims abstract description 42
- 241000699800 Cricetinae Species 0.000 claims abstract description 14
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 14
- 210000004556 brain Anatomy 0.000 claims abstract description 9
- 230000003612 virological effect Effects 0.000 claims abstract description 7
- 238000011534 incubation Methods 0.000 claims abstract description 6
- 206010037742 Rabies Diseases 0.000 claims abstract description 5
- 210000003079 salivary gland Anatomy 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 27
- 238000010790 dilution Methods 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 210000004072 lung Anatomy 0.000 claims description 5
- 241000711798 Rabies lyssavirus Species 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229960000380 propiolactone Drugs 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 210000005265 lung cell Anatomy 0.000 abstract description 6
- 241000282421 Canidae Species 0.000 abstract description 3
- 239000002356 single layer Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 description 14
- 239000000725 suspension Substances 0.000 description 12
- 241000282485 Vulpes vulpes Species 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20161—Methods of inactivation or attenuation
- C12N2760/20164—Methods of inactivation or attenuation by serial passage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8008414A FR2480123A1 (fr) | 1980-04-15 | 1980-04-15 | Nouveau vaccin contre la rage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8008414A FR2480123A1 (fr) | 1980-04-15 | 1980-04-15 | Nouveau vaccin contre la rage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2480123A1 true FR2480123A1 (fr) | 1981-10-16 |
| FR2480123B1 FR2480123B1 (enExample) | 1983-07-29 |
Family
ID=9240897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8008414A Granted FR2480123A1 (fr) | 1980-04-15 | 1980-04-15 | Nouveau vaccin contre la rage |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2480123A1 (enExample) |
-
1980
- 1980-04-15 FR FR8008414A patent/FR2480123A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| FR2480123B1 (enExample) | 1983-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rodrigues et al. | The threat of emerging and re-emerging pathogenic Sporothrix species | |
| CA1331562C (en) | Vaccine | |
| Jores et al. | Removal of a subset of non-essential genes fully attenuates a highly virulent Mycoplasma strain | |
| Avital et al. | Foliar delivery of siRNA particles for treating viral infections in agricultural grapevines | |
| Ortmann et al. | Safety studies with the oral rabies virus vaccine strain SPBN GASGAS in the small Indian mongoose (Herpestes auropunctatus) | |
| Zhugunissov et al. | Protective immune response of oral rabies vaccine in stray dogs, corsacs and steppe wolves after a single immunization | |
| JPH021807B2 (enExample) | ||
| Sarca et al. | FRET-Based Detection and Quantification of HIV-1 Virion Maturation | |
| FR2480123A1 (fr) | Nouveau vaccin contre la rage | |
| Banu et al. | Determination of immune response of Newcastle disease virus vaccines in layer chickens | |
| Apinda et al. | Efficiency of NHEJ-CRISPR/Cas9 and Cre-LoxP engineered recombinant Turkey herpesvirus expressing Pasteurella multocida OmpH protein for fowl cholera prevention in ducks | |
| CN119770635A (zh) | 一种鱼类病毒性神经坏死症重组腺病毒疫苗及其制备方法和应用 | |
| Sharif et al. | Assessment of persistence of Besnoitia besnoiti (Henry, 1913) bradyzoites in Stomoxys calcitrans (Diptera: Muscidae) | |
| EP0336956A1 (fr) | Gene recombinant defectif et activable par un transactivateur | |
| Wainberg et al. | Cellular and humoral anti‐tumor immune responsiveness in chickens bearing tumors induced by avian sarcoma virus | |
| Pratt et al. | An experiment in Denmark to infect wounded Sitka spruce with the rotstop isolate of Phlebiopsis gigantea, and its implications for the control of Heterobasidion annosum in Britain | |
| FENNER et al. | History of viral immunology | |
| JP2896494B2 (ja) | 無藻ミドリゾウリムシの創製方法及び得られた無藻ミドリゾウリムシ | |
| Csalane Besenyei | Engineering Phaeodactylum for vaccine production | |
| Mergia et al. | Simian foamy virus type 1 (SFV-1) induces apoptosis | |
| Casey et al. | Complement-fixing antibodies in monkeys bearing tumours induced by Rous sarcoma virus | |
| Damiani et al. | Wolbachia in Aedes koreicus: Rare Detections and Possible Implications. Insects 2022, 13, 216 | |
| Rupprecht | Seven Decades of Seminal Contributions on Rabies in the Journal of Wildlife Diseases | |
| Williams | Transient Expression of the Rabies Glycoprotein in Soybean | |
| Silva et al. | Effect of Trichoderma atroviride Application on Tea Yield and Its Impact on the Soil Microbiome in a New Zealand Tea Plantation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |